Christopher e Hopkins

Chief Executive Officer @Glafabra Therapeutics

Park City, UT, US
MOBILE NUMBERS
+91 *********19

Signup · Get unlimited contacts

WORK HISTORY

Sep 2024 — Present

Chief Executive Officer @Glafabra Therapeutics

View department →

At Glafabra Therapeutics we are building durable cell therapies for enzyme deficiency disorders that effect 80M patients worldwide. Our lead asset GT-GLA-S03 is in Fabry disease ant its therapeutic durability is now well documented in publications of Canadian clinical trials. Other diseases targets in metabolic disorders are under development using our STEM, TRAM and iTRAM technologies.

EDUCATION

1986 — 1991

University of Utah

BS, Biology

1997 — 2003

Boston University

Ph. D., Molecular-Cellular Biology and Biochemistry

2010 — 2012

Westminster University

Master of Business Administration (MBA), Project-based degree

SKILLS

GeneticsLicensingDrug DiscoveryLaboratoryDrug DevelopmentIntellectual PropertySequencingHplcResearchGenomicsTechnology TransferLifesciencesProtein ExpressionAssay DevelopmentLife SciencesPcrWestern BlottingPharmaceutical IndustryBiochemistryNmrMolecular BiologyPatentsToxicology

ABOUT CHRISTOPHER E HOPKINS

Chris is bringing to market a cell-based gene therapy to help patients with Fabry, Pompe…

This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.